<DOC>
	<DOCNO>NCT00084916</DOCNO>
	<brief_summary>Drugs use chemotherapy CCI-779 work different way stop cancer cell divide stop grow die . This phase II trial study well CCI-779 work treat patient relapsed refractory acute myeloid leukemia , acute lymphoblastic leukemia , myelodysplastic syndrome , chronic myelogenous leukemia blastic phase</brief_summary>
	<brief_title>CCI-779 Treating Patients With Relapsed Refractory Acute Myeloid Leukemia , Acute Lymphoblastic Leukemia , Myelodysplastic Syndromes , Chronic Myelogenous Leukemia Blastic Phase</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine activity CCI-779 patient relapse refractory acute myeloid leukemia , acute lymphoblastic leukemia , myelodysplastic syndrome , chronic myelogenous leukemia blastic phase . II . Correlate effect drug alter mitochondrial respiration leukemia cell patient . OUTLINE : Patients stratify accord disease ( acute myeloid leukemia , myelodysplastic syndrome , chronic myelogenous leukemia blastic phase [ CML-BP ] non-lymphoid v acute lymphoblastic leukemia , CML-BP lymphoid ) . Patients receive CCI-779 IV 30 minute day 1 , 8 , 15 , 22 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients follow every 2 month . PROJECTED ACCRUAL : A total 24-74 patient ( 12-37 per stratum ) accrue study within 8-46 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Diagnosis 1 follow : Acute myeloid leukemia Acute lymphoblastic leukemia Myelodysplastic syndromes Refractory anemia excess blast [ RAEB ] RAEB transformation Chronic myelomonocytic leukemia transformation ≥ 10 % peripheral blood/bone marrow blast Chronic myelogenous leukemia blastic phase Disease status must meet 1 follow criterion : Primary resistant disease ( i.e. , fail achieve complete response [ CR ] prior standard induction regimen ) Relapsed disease achieve CR Documented failure recent cytotoxic regimen No potentially curative option No know CNS disease Performance status ECOG 02 SGOT SGPT &lt; 3 time upper limit normal* Bilirubin ≤ 2 mg/dL* Creatinine ≤ 2 mg/dL ( unless due organ leukemic involvement ) No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior allergic reaction attribute compound similar chemical biological composition CCI779 No ongoing active infection No psychiatric illness social situation would preclude study compliance No AIDSdefining disease HIV positive allow CD4 count normal No concurrent uncontrolled illness No concurrent prophylactic hematopoietic colonystimulating factor More 2 week since prior cytotoxic chemotherapy ( except hydroxyurea ) recover More 2 week since prior radiotherapy recover No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational agent No concurrent anticancer agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>